TD Cowen analyst Joseph Thome initiated coverage of Bright Minds (DRUG) with a Buy rating and no price target The company’s lead asset BMB-101 is a biased 5-HT2C agonist that has the potential to be best in class for the treatment of certain refractory seizure disorders, the analyst tells investors in a research note. The firm says its key opinion leaders have highlighted the unmet need by current options in absence epilepsy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRUG:
- Bright Minds Biosciences’ BMB-101: A Promising Anti-Seizure Drug with Billion-Dollar Market Potential
- Psychedelic: Compass, GH Research, MindMed report quarterly earnings
- AMD upgraded, Electronic Arts downgraded: Wall Street’s top analyst calls
- Bright Minds initiated with a Buy at Chardan
- Bright Minds Biosciences to Host Virtual R&D Day on Epilepsy Research